Does the media refer more to CRSP or ALLO?

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AXSM or CRSP?

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 13 articles in the media. Axsome Therapeutics' average media sentiment score of 0.84 beat CRISPR Therapeutics' score of 0.64 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BEAM or CRSP?

In the previous week, CRISPR Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 12 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Beam Therapeutics' score of 0.18 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or CRSP?

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.64 beat Editas Medicine's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is KALA or CRSP more profitable?

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% CRISPR Therapeutics -13,856.54% -25.66% -20.39%

Does the media prefer KALA or CRSP?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 3 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.64 beat KALA BIO's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

CRISPR Therapeutics (CRSP) Competitors

$53.35 -2.99 (-5.31%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$53.86 +0.51 (+0.96%)

As of 07/10/2026 07:59 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? MarketBeat compares CRISPR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

CRISPR Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A
Allogene Therapeutics	$20K	34,515.00	-$190.89M	-$0.77	N/A

CRISPR Therapeutics presently has a consensus price target of $67.78, suggesting a potential upside of 27.04%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 326.11%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Axsome Therapeutics has a net margin of -26.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 13 articles in the media. Axsome Therapeutics' average media sentiment score of 0.84 beat CRISPR Therapeutics' score of 0.64 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.84	-$183.17M	-$3.73	N/A
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics currently has a consensus target price of $259.05, indicating a potential upside of 10.80%. CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 27.04%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Axsome Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.06	-$79.99M	-$0.68	N/A
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beam Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 12 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Beam Therapeutics' score of 0.18 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Beam Therapeutics currently has a consensus price target of $46.85, indicating a potential upside of 43.35%. CRISPR Therapeutics has a consensus price target of $67.78, indicating a potential upside of 27.04%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Beam Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.88	-$160.06M	-$1.23	N/A
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A

Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Editas Medicine presently has a consensus price target of $5.40, indicating a potential upside of 65.64%. CRISPR Therapeutics has a consensus price target of $67.78, indicating a potential upside of 27.04%. Given Editas Medicine's higher possible upside, equities analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.64 beat Editas Medicine's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

CRISPR Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

KALA BIO presently has a consensus price target of $1,158.33, suggesting a potential upside of 98,481.56%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 27.04%. Given KALA BIO's higher probable upside, equities analysts plainly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

KALA BIO has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A

In the previous week, CRISPR Therapeutics had 10 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 3 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.64 beat KALA BIO's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CRISPR Therapeutics beats KALA BIO on 12 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.43B	$3.79B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-8.58	21.27	27.22	24.56
Price / Sales	1,465.99	323.90	590.16	121.71
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	2.65	8.41	10.90	6.39
Net Income	-$581.60M	$23.85M	$3.57B	$331.44M
7 Day Performance	-11.20%	-0.76%	-0.25%	0.37%
1 Month Performance	6.21%	11.35%	5.77%	2.17%
1 Year Performance	-6.07%	51.68%	28.14%	20.90%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	3.7183 of 5 stars	$53.35 -5.3%	$67.78 +27.0%	-9.6%	$5.43B	$3.51M	N/A	460	Analyst Forecast
ALLO Allogene Therapeutics	2.336 of 5 stars	$2.22 +4.2%	$8.52 +283.9%	+58.7%	$766.23M	$20K	N/A	310	News Coverage Positive News
AXSM Axsome Therapeutics	3.6712 of 5 stars	$241.12 -0.2%	$258.95 +7.4%	+111.1%	$12.41B	$708.24M	N/A	380	News Coverage Analyst Forecast
BEAM Beam Therapeutics	3.2841 of 5 stars	$34.95 +0.4%	$46.83 +34.0%	+48.3%	$3.60B	$164.01M	N/A	510	News Coverage Analyst Forecast
EDIT Editas Medicine	2.1961 of 5 stars	$3.20 +12.3%	$5.40 +68.8%	+6.5%	$313.30M	$38.69M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Which has more volatility and risk, CRSP or ALLO?

Is CRSP or ALLO more profitable?

Does the media refer more to CRSP or ALLO?

Do institutionals & insiders hold more shares of CRSP or ALLO?

Which has stronger valuation & earnings, CRSP or ALLO?

Do analysts prefer CRSP or ALLO?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Is AXSM or CRSP more profitable?

Does the media prefer AXSM or CRSP?

Which has preferable valuation and earnings, AXSM or CRSP?

Do institutionals and insiders have more ownership in AXSM or CRSP?

Do analysts recommend AXSM or CRSP?

Which has more volatility and risk, AXSM or CRSP?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has better earnings and valuation, BEAM or CRSP?

Do institutionals & insiders have more ownership in BEAM or CRSP?

Which has more risk and volatility, BEAM or CRSP?

Does the media favor BEAM or CRSP?

Is BEAM or CRSP more profitable?

Do analysts rate BEAM or CRSP?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Which has higher earnings and valuation, EDIT or CRSP?

Which has more volatility and risk, EDIT or CRSP?

Do analysts recommend EDIT or CRSP?

Do insiders and institutionals have more ownership in EDIT or CRSP?

Does the media favor EDIT or CRSP?

Is EDIT or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Is KALA or CRSP more profitable?

Which has more volatility and risk, KALA or CRSP?

Do insiders & institutionals hold more shares of KALA or CRSP?

Do analysts rate KALA or CRSP?

Which has preferable earnings & valuation, KALA or CRSP?

Does the media prefer KALA or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools